U.S. Antibiotic Resistance Market (2025 - 2030) Size, Share, & Trends Analysis Report By Disease (cUTI, CDI), By Pathogen, By Drug Class, By Mechanism of Action, By Distribution Channel, And Segment Forecasts

Market Segmentation

U.S. Antibiotic Resistance Disease Outlook (Revenue in USD Million, 2018 - 2030)
- cUTI
- CDI
- ABSSSI
- HABP
- CABP
- cIAI
- BSI
U.S. Antibiotic Resistance Pathogen Outlook (Revenue in USD Million, 2018 - 2030)
- E. coli
- klebsiella pneumoniae
- P. aeruginosa
- S. aureus
- A. baumannii
- Strep. Pneumoniae
- H. influenzae
- CDI
- Enterococcus fecium
U.S. Antibiotic Resistance Drug Class Outlook (Revenue in USD Million; 2018 - 2030)
- Oxazolidinones
- Lipoglycopeptides
- Tetracyclines
- Combination therapies
- Cephalosporins
- Others
U.S. Antibiotic Resistance Mechanism of Action Outlook (Revenue in USD Million; 2018 - 2030)
- Protein Synthesis Inhibitors
- Cell Wall Synthesis Inhibitors
- RNA Synthesis Inhibitors
- DNA Synthesis Inhibitors
- Others
U.S. Antibiotic Resistance Distribution Channel Outlook (Revenue in USD Million; 2018 - 2030)
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments